Psychiatry

Back to articles

Clozapine Superior in Patients with Treatment-Resistant Schizophrenia

KEY POINT

In patients with chronic refractory schizophrenia, a trial of clozapine is worthwhile even though other typical and atypical antipsychotic agents have failed, according to a meta-analysis of 12 controlled studies. While clozapine’s effects were not “robust,” but clinical results with the other atypical agents were inconclusive.

SOURCES

Chakos M et al. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry. 2001;158:518–26.